Corporate VCs Wade In With Funds To Pursue Gene Therapy For Wilson Disease

Rare copper-overload disorder Wilson disease is seeing a surge of interest: one new copper chelator recently garnered a CHMP recommendation, a novel copper modulator has had promising Phase II data, and French biotech Vivet has secured significant funds to pursue a gene therapy approach to the disease.

Wilson's disease

Potential new treatments for the for the rare, inherited metabolic condition Wilson disease are hoping to fill the unmet need in the disease despite the availability of older products that chelate copper in the blood. Just recently a new copper chelator was given a green light by the EMA's advisory committee (gmp-orphan's Cuprior (trientine base). Meanwhile, Swedish biotech Wilson Therapeutics AB recently reported positive Phase II data with its copper modulating agent WTX101 (bis-choline tetrathiomolybdate), a novel approach to treating the condition. (Also see "Wilson Therapeutics Progressing Its Copper Modulating Agent To Phase III" - Scrip, 5 December, 2016.)

[Sidebar#PS120480]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip